EB-003

Uses your system voice; voice and rate in settings.

Snapshot

≈ 3 min read

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

EB-003 is a non-hallucinogenic serotonin receptor agonist which is under development for the treatment of depressive disorders and anxiety disorders. It is a tryptamine and a derivative of the serotonergic psychedelic dimethyltryptamine (DMT). The drug acts as a non-selective agonist of serotonin receptors, including of the serotonin 5-HT 1A , 5-HT 1B , and 5-HT 2A receptors. It is not a serotonin 5-HT 2B receptor agonist. EB-003 produces psychoplastogenic effects. Due to targeting not only the serotonin 5-HT 2A receptor but also the serotonin 5-HT 1B receptor to influence neuroplasticity, EB-003 has been branded a new type of drug called a "neurostabilogen" by its developer. EB-003 is being developed by Enveric Biosciences. As of February 2025, it is in the preclinical research stage of development. A phase 1 clinical trial is being planned. The drug's exact chemical structure does not yet seem to have been disclosed. It has been patented, though the patent does not yet appear to have been published.

EB-003 is a non-hallucinogenic serotonin receptor agonist which is under development for the treatment of depressive disorders and anxiety disorders. It is a tryptamine and a derivative of the serotonergic psychedelic dimethyltryptamine (DMT). The drug acts as a non-selective agonist of serotonin receptors, including of the serotonin 5-HT 1A , 5-HT 1B , and 5-HT 2A receptors. It is not a serotonin 5-HT 2B receptor agonist. EB-003 produces psychoplastogenic effects. Due to targeting not only the serotonin 5-HT 2A receptor but also the serotonin 5-HT 1B receptor to influence neuroplasticity, EB-003 has been branded a new type of drug called a "neurostabilogen" by its developer. EB-003 is being developed by Enveric Biosciences. As of February 2025, it is in the preclinical research stage of development. A phase 1 clinical trial is being planned. The drug's exact chemical structure does not yet seem to have been disclosed. It has been patented, though the patent does not yet appear to have been published.

See also

EB-002 List of investigational hallucinogens and entactogens List of investigational antidepressants Non-hallucinogenic 5-HT 2A receptor agonist

References

Text derived from https://en.wikipedia.org/w/index.php?oldid=1318154388 under CC BY-SA 4.0; modifications have been made.

Sources cited in this revision

7 named source(s) extracted from the cited revision. A source with no author is shown by its publication; nothing is invented.